Strategy chairman Michael Saylor still hasn't won over the institutional space. Illustration: Gwen P; Source: ShutterstockStrategy chairman Michael Saylor still hasn't won over the institutional space. Illustration: Gwen P; Source: Shutterstock

Why these three ‘narrative barriers’ pose clear risks to the Strategy Bitcoin scheme, says analyst

2026/03/25 12:01
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Strategy might be on track to overtake BlackRock as the world’s largest corporate Bitcoin holder. But Michael Saylor’s firm still faces three “narrative barriers” that could slow it down.

One is concentration risk, said James Seyffart, a fund expert at Bloomberg Intelligence.

If an institutional investor who knows nothing about the Bitcoin space sees that a majority of the token’s supply is owned by a single company, “I’m going to be a little bit skeptical,” Seyffart said on the Bitcoin History podcast on March 24.

The other two include qualms about quantum computing and concerns about portfolio diversification.

“These are all things that are just going to be barriers,” he said.

Investors unwilling to buy up Strategy stock could have serious negative repercussions for Bitcoin, too.

If investment into Strategy co-founder Michael Saylor dries up, his firm’s ability to buy up more Bitcoin would also slow — effectively stopping one of the biggest Bitcoin buyers on the planet from more purchases.

Concentration risk

Right now, Strategy owns more than 720,000 Bitcoin worth around $53 billion.

That’s around 3.5% of Bitcoin’s total supply in the hands of Michael Saylor.

For Seyffart, the power that Saylor commands over his own company is a risk that’s simply too hard to ignore.

“Saylor doesn’t own full voting control, but he owns a lot of it and de facto control right now,” Seyffart said. “He has a lot of control over a significant portion of Bitcoin’s outstanding balance and future outstanding balance.”

Institutions don’t like that, noted Seyffart.

Quantum computing

Then there’s quantum computing.

“Obviously, I do hear people from the traditional fianncial world asking me what’s going on with quantum computing,” said Seyffart. “That’s another risk that people are asking about.”

Over the last year or so, the Bitcoin community has been embroiled in a heated debate over how to address the alleged threat of quantum computers, a still-theoretical yet rapidly progressing technology that could break the encryption that secures the Bitcoin network.

Researchers at Chaincode Labs have published estimates that up to 50% of all Bitcoin could be vulnerable to a quantum attack.

Diversification risk

The third barrier is diversification.

Endowments and sovereign wealth funds building crypto allocations may baulk at a market where a single entity controls an ever-growing share of supply, regardless of whether that control is direct or distributed across shareholders, Seyffart noted.

Even so, Seyffart doesn’t think any one of these concerns, on its own, is enough to bring down Strategy.

“I don’t have any blatant ‘this domino is going to fall and cause all these dominoes to fall,’ he said.

“It’s more just like, obviously this is something that people are going to point to.”

Pedro Solimano is a markets correspondent based in Buenos Aires. Got a tip? Email him at [email protected].

Market Opportunity
Spacecoin Logo
Spacecoin Price(SPACE)
$0.006668
$0.006668$0.006668
+5.37%
USD
Spacecoin (SPACE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

CME Group to launch options on XRP and SOL futures

CME Group to launch options on XRP and SOL futures

The post CME Group to launch options on XRP and SOL futures appeared on BitcoinEthereumNews.com. CME Group will offer options based on the derivative markets on Solana (SOL) and XRP. The new markets will open on October 13, after regulatory approval.  CME Group will expand its crypto products with options on the futures markets of Solana (SOL) and XRP. The futures market will start on October 13, after regulatory review and approval.  The options will allow the trading of MicroSol, XRP, and MicroXRP futures, with expiry dates available every business day, monthly, and quarterly. The new products will be added to the existing BTC and ETH options markets. ‘The launch of these options contracts builds on the significant growth and increasing liquidity we have seen across our suite of Solana and XRP futures,’ said Giovanni Vicioso, CME Group Global Head of Cryptocurrency Products. The options contracts will have two main sizes, tracking the futures contracts. The new market will be suitable for sophisticated institutional traders, as well as active individual traders. The addition of options markets singles out XRP and SOL as liquid enough to offer the potential to bet on a market direction.  The options on futures arrive a few months after the launch of SOL futures. Both SOL and XRP had peak volumes in August, though XRP activity has slowed down in September. XRP and SOL options to tap both institutions and active traders Crypto options are one of the indicators of market attitudes, with XRP and SOL receiving a new way to gauge sentiment. The contracts will be supported by the Cumberland team.  ‘As one of the biggest liquidity providers in the ecosystem, the Cumberland team is excited to support CME Group’s continued expansion of crypto offerings,’ said Roman Makarov, Head of Cumberland Options Trading at DRW. ‘The launch of options on Solana and XRP futures is the latest example of the…
Share
BitcoinEthereumNews2025/09/18 00:56
Why YouCam AI API is the Secret Weapon for E-Commerce Startups

Why YouCam AI API is the Secret Weapon for E-Commerce Startups

 The New Standard of Personalized Shopping In an era where digital engagement dictates market share, the transition from “browsing” to “buying” depends on confidence
Share
Techbullion2026/03/25 14:34
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26